What's Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics.

Das, Ritam; Kanjilal, Pintu; Medeiros, Jewel; Thayumanavan, S

Das, Ritam; Kanjilal, Pintu; Medeiros, Jewel; Thayumanavan, S.

Afiliação

Das R; Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States.
Kanjilal P; The Center for Bioactive Delivery-Institute for Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.
Medeiros J; Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States.
Thayumanavan S; The Center for Bioactive Delivery-Institute for Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.

Bioconjug Chem ; 33(11): 1996-2007, 2022 11 16.

Article em En | MEDLINE | ID: mdl-35377622

Assuntos

COVID-19; Nanopartículas; Ácidos Nucleicos; Humanos; Ácidos Nucleicos/uso terapêutico; Vacinas contra COVID-19; Estudos Prospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Nucleicos / Nanopartículas / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google